Approved in combination with fluoracil and leucovorin to treat metastatic pancreatic cancer.
Approved as secondline treatment for metastatic pancreatic cancer.
In the NAPOLI study that included 417 patients metastatic pancreatic cancer that progressed after they have failed treatment with gemcitibine and those who took irinotecan with fluoracil and leucovorin lived an average of 6.1 months compared to 4.2 months for those treated only with fluorocil and leucovorin.
Common side effects include diarrhea, fatigue, nausea, vomiting, anorexia, stomatitis, and fever.
80-120mg/m2 every 2-3 weeks.